Understanding and Targeting Lineage Plasticity in Prostate Cancer with Genomic-Based Neoadjuvant Therapy
Official title: Project 2: Understanding and Targeting the Lineage plasticity in the Genomic Umbrella Neoadjuvant Study (GUNS)
Funded at Fred Hutchinson Cancer Center · NIH-11625620 · Data updated 2026-11-12
A broad research program at Fred Hutchinson Cancer Center is exploring how aggressive prostate cancers change their cell states in response to therapy and how to block these changes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 19, 2002 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $211,901 |
| NIH project number | 3P50CA097186-25S1 |
| Project ID | NIH-11625620 on NIH RePORTER |
Who could benefit from this research
✓Could help
Men with advanced or metastatic prostate cancer receiving AR pathway inhibitor therapy or in similar biomarker-defined strata.
✕Less likely to help
Patients whose cancer does not show lineage plasticity or whose tumors do not fit the biomarker criteria may derive limited benefit.
What this research studies
This project uses a multi-stage, multi-arm neoadjuvant design to study how advanced prostate cancers adapt their cell programs when exposed to potent AR pathway inhibitors. It combines clinical samples with molecular profiling to map the changes and identify potential therapeutic angles. The goal is to inform future treatments that can prevent or overcome resistance, improving outcomes for men with metastatic disease.
Why it matters
Potential benefit: If successful, findings could lead to smarter combination therapies that delay resistance and extend survival for patients with aggressive prostate cancer.
How similar studies have gone: Previous studies have shown that lineage plasticity and neuroendocrine features can emerge under AR-targeted therapies, indicating this approach is clinically relevant but still largely exploratory.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Gleave, Martin Edwin — Fred Hutchinson Cancer Center
- Study coordinator: Gleave, Martin Edwin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.